Japan Fabry Research - 001

Japan Fabry Research - 001 - JFR - 001

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1090220293

Enrollment

Registered

2017-05-26

Start date

2006-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry disease

Interventions

Intervention type: Name of intervention: Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration: Dosing frequency / Frequency of use:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) ERT treatment-naive patients with Fabry disease 2) Patients receiving treatment with agalsidase alfa 0.2 mg/kg every two weeks

Exclusion criteria

Exclusion criteria: Patients with E66Q amino acid substitution

Design outcomes

Primary

Measure	Time frame
The parameters measured included globotriaosylceramide (Gb3), globotriaosylsphingosine (Lyso-Gb3), left ventricular mass index (LVMI), brain natriuretic peptide (BNP), high-sensitivity troponin I (hs-Trop I), estimated glomerular filtration rate (eGFR), and anti-agalsidase alfa IgG antibody formation.	—

Countries

Japan

Contacts

Public ContactKazuya Tsuboi

Nagoya Central Hospital

kazuya.tsuboi@jr-central.co.jp+81-52-452-3165

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026